



ms

0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Gerritsen and Rastelli)	ATTY. DOCKET NO.
)	09800081-0023
SERIAL NO.	09/784,810)	GROUP ART UNIT: Unknown
DATE FILED:	February 14, 2001)	EXAMINER: Unknown
INVENTION:	NOVEL SPHINGOSINE KINASES)	
	AND NUCLEIC ACIDS)	
	ENCODING SAME)	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated September 16, 2002, enclosed is a computer readable form (CRF) copy of the "Sequence Listing", a paper copy of the "Sequence Listing" and a Statement verifying that the information on the accompanying diskette is identical to the written sequence listing.


The Commissioner is authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 19-3140.

Respectfully submitted,

Gregory M. Zinkl (Reg. No. 48,492)
Gregory M. Zinkl, Ph.D.
SONNENSCHN NATH & ROSENTHAL
P.O. Box #061080
Wacker Drive Station - Sears Tower
Chicago, Illinois 60606-1080
Telephone 312/876-8936
Fax 312/876-7934
Customer #26263
Agent for Applicants

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on October 16, 2002

#13




Gregory M. Zinkl, Ph.D., Registered Representative

October 16, 2002

Date

Case No. 9800081-0023



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		Attention: Manager, Application Branch
	Gerritsen and Rastelli	
Serial No.:	09/784,810	
Filed:	02/14/2001	
For:	NOVEL SPHINGOSINE KINASES AND NUCLEIC ACIDS ENCODING SAME	

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

BOX SEQUENCE LISTING


Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Submitted herewith is a sequence listing as part of the above-captioned patent application. Applicants' representative states that the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicants' representative hereby verifies that the information on the accompanying diskette is identical to the written sequence listing. The enclosed sequence listing does not include any new matter that goes beyond the disclosure in the captioned application as filed.

Respectfully submitted


Gregory M. Zinkl, Ph.D.
Reg. No. 48,492

SONNENSCHN NATH & ROSENTHAL
P.O. Box #061080
Wacker Drive Station
Sears Tower
Chicago, Illinois 60606-1080

Direct telephone calls to:

(312) 876-8936



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/784,810	02/14/2001	Mary E. Gerritsen	10716/8

28443
BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, IL 60610



CONFIRMATION NO. 4070
FORMALITIES LETTER



OC000000008787538

Date Mailed: 09/16/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

BZ

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE